- Home
- SUNS vs IPHA Comparison
SUNS vs IPHA Comparison
Compare SUNS & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUNS
- IPHA
- Stock Information
- Founded
- SUNS 2023
- IPHA 1999
- Country
- SUNS United States
- IPHA France
- Employees
- SUNS N/A
- IPHA N/A
- Industry
- SUNS Real Estate Investment Trusts
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- SUNS Real Estate
- IPHA Health Care
- Exchange
- SUNS Nasdaq
- IPHA Nasdaq
- Market Cap
- SUNS 148.0M
- IPHA 160.1M
- IPO Year
- SUNS N/A
- IPHA 2019
- Fundamental
- Price
- SUNS $9.94
- IPHA N/A
- Analyst Decision
- SUNS Strong Buy
- IPHA Hold
- Analyst Count
- SUNS 3
- IPHA 2
- Target Price
- SUNS $13.58
- IPHA $2.00
- AVG Volume (30 Days)
- SUNS 73.0K
- IPHA 20.0K
- Earning Date
- SUNS 11-13-2025
- IPHA 09-17-2025
- Dividend Yield
- SUNS 12.06%
- IPHA N/A
- EPS Growth
- SUNS N/A
- IPHA N/A
- EPS
- SUNS 1.04
- IPHA N/A
- Revenue
- SUNS $16,359,932.00
- IPHA $14,839,695.00
- Revenue This Year
- SUNS $183.25
- IPHA $350.96
- Revenue Next Year
- SUNS $62.46
- IPHA $32.92
- P/E Ratio
- SUNS $9.54
- IPHA N/A
- Revenue Growth
- SUNS 1342.10
- IPHA N/A
- 52 Week Low
- SUNS $7.80
- IPHA $1.29
- 52 Week High
- SUNS $15.74
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- SUNS 34.63
- IPHA N/A
- Support Level
- SUNS $9.77
- IPHA N/A
- Resistance Level
- SUNS $10.29
- IPHA N/A
- Average True Range (ATR)
- SUNS 0.31
- IPHA 0.00
- MACD
- SUNS -0.14
- IPHA 0.00
- Stochastic Oscillator
- SUNS 6.20
- IPHA 0.00
About SUNS Sunrise Realty Trust Inc. Common Stock
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.